Tech Company Inital Public Offerings
Imara Inc. IPO
Headquartered in Cambridge, Imara Inc. is now a public company.
Transaction Overview
Company Name
Announced On
3/11/2020
Transaction Type
IPO
Amount
$72,000,000
Proceeds Purpose
We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, to advance development of IMR-687 for the treatment of patients with SCD and ß-thalassemia and for working capital and other general corporate purposes, including potential pipeline expansion.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
700 Technology Sq. 3rd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Imara Inc. (Nasdaq: IMRA), is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Ballal
Chief Medical Officer
ShiYin Foo
VP - Regulatory Affairs
Kevin Johnson
Browse more venture capital transactions:
Prev: 3/11/2020: Coursedog venture capital transaction
Next: 3/11/2020: Inbox Health venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs